At present, the ICIs permitted by the FDA to treat cancer mainly target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-ligand 1 (L1) (2). This evidence concerns the gene PDCD1 and cancer.